FDA approves first dermal filler for acne scars; Teva rolls out copy of Pfizer's Zyvox antibiotic;

@FiercePharma: Hello, hep C pricing war: Gilead hits back at AbbVie with exclusive CVS deal. More | Follow @FiercePharma

@CarlyHFierce: NPS is officially up for sale. Will deal-minded Shire bid? Story | Follow @CarlyHFierce

> Suneva Medical won FDA approval for Bellafill, the first dermal filler cleared specifically to treat scarring caused by acne. Report

> Teva Pharmaceutical Industries ($TEVA) rolled out generic versions of two antibiotics in the U.S., including a copy of Pfizer's ($PFE) blockbuster Zyvox. Report

> Bayer HealthCare chose Onco360, a specialty distributor focusing on cancer products, to distribute its cancer drugs Nexavar and Stivarga as part of a limited distribution plan for those meds. Release

> Ariad Pharmaceuticals ($ARIA) inked a licensing deal with Italy-based Angelini Pharma to push its cancer drug Iclusig into 23 markets in Eastern Europe. Report

> After allowing several Big Pharma cancer drugs to be approved without local trials, Indian officials are now asking the makers of those therapies to monitor them for post-marketing safety. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA approves Medtronic's drug-coated balloon, setting up clash with Bard in new U.S. market. Article | Follow @FierceMedDev

@EmilyWFierce: Covidien shareholders approve proposed $43B merger with Medtronic; Medtronic shareholder vote TK. Article | Follow @EmilyWFierce

> Qualcomm to connect medical devices to cloud for Walgreens, Novartis. Report

> Health devices take the stage at Consumer Electronics Show. Story

Biotech News

@FierceBiotech: A record year for biotech inspires some great expectations for 2015. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Third Rock-backed GBT bags $48M round, plots upcoming IPO. Report | Follow @JohnCFierce

@DamianFierce: $GUD's CEO says he got so many calls about FDA priority review voucher that Knight may make a business out of it. More from Bloomberg | Follow @DamianFierce

> Tracon eyes a $57.5M IPO to get its cancer drug into Phase III. Report

> Gilead buys its way into the blockbuster NASH race with $470M deal. Article

> The biotech blitz: Seres Health lands $65M for PhIII C. diff push. News

> CytomX bags $20M for its novel antibodies with Pfizer leading the charge. Article

> Moderna hauls in $450M to push its pioneering approach to mRNA. News

Biotech Research News

> Mouse study points to a particular T cell target for diabetes, insulin resistance. Report

> Cold Spring Harbor scientists find a biomarker for p53 cancer mutations. Item

> Positive primate study for Parkinson's inspires a rally for Minerva. Story

> Johns Hopkins stem cell team tests out CRISPR tech, with encouraging results. More

> CHOP scientists herald new approach to neurodegenerative diseases. Article

Pharma Manufacturing News

> Hospira recalls cancer med that was focus of warning letter. More

> FDA delays enforcing track-and-trace rules by four months. Report

> FDA sends warning letter to China's Novacyl Wuxi. News

> Patients had problems after being given IVs intended for training, FDA reports. Story

> Valeant says inhaled drug used on infants may be contaminated. Article

And Finally... Here are some unintended consequences: Bayer issues a 3-bottles-for-$10 coupon on Bayer Aspirin. Wal-Mart's price is $2.17. So, coupon users pocket the difference in cash. Report

Suggested Articles

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.